BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 32094298)

  • 1. Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.
    Hankey W; Chen Z; Wang Q
    Cancer Res; 2020 Jun; 80(12):2427-2436. PubMed ID: 32094298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.
    Wu D; Sunkel B; Chen Z; Liu X; Ye Z; Li Q; Grenade C; Ke J; Zhang C; Chen H; Nephew KP; Huang TH; Liu Z; Jin VX; Wang Q
    Nucleic Acids Res; 2014 Apr; 42(6):3607-22. PubMed ID: 24423874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
    Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
    Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
    Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
    Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
    Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
    Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer.
    Chaytor L; Simcock M; Nakjang S; Heath R; Walker L; Robson C; Jones D; Gaughan L
    Mol Cancer Res; 2019 Jun; 17(6):1264-1278. PubMed ID: 30833300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.
    He Y; Lu J; Ye Z; Hao S; Wang L; Kohli M; Tindall DJ; Li B; Zhu R; Wang L; Huang H
    Nucleic Acids Res; 2018 Feb; 46(4):1895-1911. PubMed ID: 29309643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
    Shen T; Dong B; Meng Y; Moore DD; Yang F
    Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2205350119. PubMed ID: 36251994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
    Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
    Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Chen Z; Wu D; Thomas-Ahner JM; Lu C; Zhao P; Zhang Q; Geraghty C; Yan PS; Hankey W; Sunkel B; Cheng X; Antonarakis ES; Wang QE; Liu Z; Huang TH; Jin VX; Clinton SK; Luo J; Huang J; Wang Q
    Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6810-6815. PubMed ID: 29844167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
    Jin HJ; Zhao JC; Wu L; Kim J; Yu J
    Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.
    Stelloo S; Nevedomskaya E; Kim Y; Hoekman L; Bleijerveld OB; Mirza T; Wessels LFA; van Weerden WM; Altelaar AFM; Bergman AM; Zwart W
    Oncogene; 2018 Jan; 37(3):313-322. PubMed ID: 28925401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCAR1 promotes chromatin loading of androgen receptor (AR) transcription complex by stabilizing the association between AR and GATA2.
    Seo WY; Jeong BC; Yu EJ; Kim HJ; Kim SH; Lim JE; Kwon GY; Lee HM; Kim JH
    Nucleic Acids Res; 2013 Oct; 41(18):8526-36. PubMed ID: 23887938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression.
    Shah S; Prasad S; Knudsen KE
    Cancer Res; 2012 Mar; 72(5):1248-59. PubMed ID: 22258452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of GATA2 in prostate cancer by a clinically available small molecule.
    Kaochar S; Rusin A; Foley C; Rajapakshe K; Robertson M; Skapura D; Mason C; Berman De Ruiz K; Tyryshkin AM; Deng J; Shin JN; Fiskus W; Dong J; Huang S; Navone NM; Davis CM; Ehli EA; Coarfa C; Mitsiades N
    Endocr Relat Cancer; 2021 Nov; 29(1):15-31. PubMed ID: 34636746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioneer of prostate cancer: past, present and the future of FOXA1.
    Teng M; Zhou S; Cai C; Lupien M; He HH
    Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.
    He B; Lanz RB; Fiskus W; Geng C; Yi P; Hartig SM; Rajapakshe K; Shou J; Wei L; Shah SS; Foley C; Chew SA; Eedunuri VK; Bedoya DJ; Feng Q; Minami T; Mitsiades CS; Frolov A; Weigel NL; Hilsenbeck SG; Rosen DG; Palzkill T; Ittmann MM; Song Y; Coarfa C; O'Malley BW; Mitsiades N
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18261-6. PubMed ID: 25489091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
    Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
    Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.